WVE Wave Life Sciences
- 6.200
- -0.040-0.64%
- 6.300
- +0.100+1.61%
Wave Life Sciences News
Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today
PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna
Wells Fargo Starts Wave Life Sciences at Buy, Cites Valuation
WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on WAVE Life Sciences (NASDAQ:WVE) in the last three months.The table below summarizes their recent
WAVE Life Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 88.36% Wells Fargo → $11 Initiates Coverage On → Overweight 04/01/2024 191.1% Truist Securities
Express News | Wave Life Sciences Ltd : Wells Fargo Initiates With Overweight Rating; Price Target $11
Buy Rating on Wave Life Sciences: Promising Pipeline and Market Potential
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Wave Life Sciences (WVE) and Intellia Therapeutics (NTLA)
On-Demand Stepped Care Mental Health Provider Wave Now In-Network For 3 Million Aetna California Members
Leapfrogging 'once per week' care delivery models, Wave meets members where they are, with board-certified mental health coaches, licensed therapists and 24/7 access to byte-sized, evidence-based, in
Bullish: Analysts Just Made A Substantial Upgrade To Their Wave Life Sciences Ltd. (NASDAQ:WVE) Forecasts
Wave Life Sciences Ltd. (NASDAQ:WVE) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The consensus statutory numbers
Wave Life Sciences Ltd. (NASDAQ:WVE) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2024 Earnings Call Transcript
WAVE Life Sciences Reports First Quarter 2024 Financial Results
Wave Life Sciences | 10-Q: Quarterly report
Buy Rating Affirmed on Wave Life Sciences With Promising Obesity and AATD Programs
Express News | Wave Life Sciences Ltd : Raymond James Raises Target Price to $11 From $10
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Earnings Call Summary | Wave Life Sciences(WVE.US) Q1 2024 Earnings Conference
The following is a summary of the Wave Life Sciences Ltd. (WVE) Q1 2024 Earnings Call Transcript:Financial Performance:Wave Life Sciences reported first quarter revenue of $12.5 million, primarily dri
Wave Life Sciences Ltd. (WVE) Q1 2024 Earnings Call Transcript
Wave Life Sciences Ltd. (WVE) Q1 2024 Earnings Call Transcript
Wave Life Sciences Releases Updated Corporate Overview
Analysis
Price Target
No Data
